https://ir.corbuspharma.com/news-events/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/_dc5231ac157b9ee4fb322b64fcb7a082/corbuspharma/files/theme/images/logo-sm.png Equisolve Investor Relations Suite https://ir.corbuspharma.com/news-events/press-releases/detail/482/corbus-pharmaceuticals-reports-q3-2026-financial-results-and-provides-a-corporate-update Tue, 10 Nov 26 08:00:00 -0500 https://ir.corbuspharma.com/news-events/press-releases/detail/482/corbus-pharmaceuticals-reports-q3-2026-financial-results-and-provides-a-corporate-update https://ir.corbuspharma.com/news-events/press-releases/detail/481/corbus-pharmaceuticals-to-participatein-upcoming-investor-conferences-in-november Thu, 05 Nov 26 08:00:00 -0500 https://ir.corbuspharma.com/news-events/press-releases/detail/481/corbus-pharmaceuticals-to-participatein-upcoming-investor-conferences-in-november https://ir.corbuspharma.com/news-events/press-releases/detail/480/corbus-pharmaceuticals-to-present-late-breaking-crb-913-data-from-canyon-1-study-at-obesity-week-2026 Thu, 22 Oct 26 08:00:00 -0400 https://ir.corbuspharma.com/news-events/press-releases/detail/480/corbus-pharmaceuticals-to-present-late-breaking-crb-913-data-from-canyon-1-study-at-obesity-week-2026 https://ir.corbuspharma.com/news-events/press-releases/detail/479/corbus-pharmaceuticals-announces-first-patient-dosed-in-tempo-1-registrational-study-of-crb-701-in-patients-with-2l-oropharyngeal-cancer Tue, 29 Sep 26 08:00:00 -0400 https://ir.corbuspharma.com/news-events/press-releases/detail/479/corbus-pharmaceuticals-announces-first-patient-dosed-in-tempo-1-registrational-study-of-crb-701-in-patients-with-2l-oropharyngeal-cancer https://ir.corbuspharma.com/news-events/press-releases/detail/478/corbus-pharmaceuticals-announces-positive-topline-data-from-canyon-1-study-of-daily-oral-crb-913-for-the-treatment-of-obesity Mon, 14 Sep 26 07:00:00 -0400 https://ir.corbuspharma.com/news-events/press-releases/detail/478/corbus-pharmaceuticals-announces-positive-topline-data-from-canyon-1-study-of-daily-oral-crb-913-for-the-treatment-of-obesity https://ir.corbuspharma.com/news-events/press-releases/detail/477/corbus-pharmaceuticals-to-host-conference-call-to-discuss-topline-data-from-canyon-1-clinical-trial-and-the-potential-of-crb-913-in-obesity Fri, 11 Sep 26 16:01:00 -0400 https://ir.corbuspharma.com/news-events/press-releases/detail/477/corbus-pharmaceuticals-to-host-conference-call-to-discuss-topline-data-from-canyon-1-clinical-trial-and-the-potential-of-crb-913-in-obesity https://ir.corbuspharma.com/news-events/press-releases/detail/476/corbus-reports-inducement-grants-under-nasdaq-listing-rule-5635c4 Mon, 17 Aug 26 10:00:00 -0400 https://ir.corbuspharma.com/news-events/press-releases/detail/476/corbus-reports-inducement-grants-under-nasdaq-listing-rule-5635c4 https://ir.corbuspharma.com/news-events/press-releases/detail/475/corbus-pharmaceuticals-reports-q2-2026-financial-results-and-provides-a-corporate-update Thu, 06 Aug 26 08:00:00 -0400 https://ir.corbuspharma.com/news-events/press-releases/detail/475/corbus-pharmaceuticals-reports-q2-2026-financial-results-and-provides-a-corporate-update https://ir.corbuspharma.com/news-events/press-releases/detail/474/corbus-pharmaceuticals-announces-last-patient-last-visit-in-canyon-1-study-of-crb-913-for-the-treatment-of-obesity Tue, 04 Aug 26 08:30:00 -0400 https://ir.corbuspharma.com/news-events/press-releases/detail/474/corbus-pharmaceuticals-announces-last-patient-last-visit-in-canyon-1-study-of-crb-913-for-the-treatment-of-obesity https://ir.corbuspharma.com/news-events/press-releases/detail/473/corbus-pharmaceuticals-announces-fda-clearance-to-initiate-tempo-1-registrational-study-of-crb-701-in-patients-with-2l-oropharyngeal-cancer Tue, 28 Jul 26 08:00:00 -0400 https://ir.corbuspharma.com/news-events/press-releases/detail/473/corbus-pharmaceuticals-announces-fda-clearance-to-initiate-tempo-1-registrational-study-of-crb-701-in-patients-with-2l-oropharyngeal-cancer